ATAI Stock Summary and Trading Ideas (Ataibeckley | NASDAQ:ATAI)

AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.

Ataibeckley trades on the NASDAQ stock market under the symbol ATAI.

As of April 2, 2026, ATAI stock price climbed to $3.79 with 2,912,508 million shares trading.

ATAI has a beta of 0.90, meaning it tends to be less sensitive to market movements. ATAI has a correlation of 0.04 to the broad based SPY ETF.

ATAI has a market cap of $1.38 billion. This is considered a Small Cap stock.

Last quarter Ataibeckley reported $1 million in Revenue and -$1.73 earnings per share. This beat revenue expectation by $328,498 and missed earnings estimates by -$1.61.

In the last 3 years, ATAI traded as high as $6.75 and as low as $1.03.

The top ETF exchange traded funds that ATAI belongs to (by Net Assets): ARKG, IBB, SCHA, PSIL, ITOT.

ATAI has outperformed the market in the last year with a price return of +205.6% while the SPY ETF gained +18.2%. However, in the short term, ATAI had mixed performance relative to the market. It has underperformed in the last 3 months, returning -7.3% vs -3.6% return in SPY. But in the last 2 weeks, ATAI shares have fared better than the market returning +6.5% compared to SPY -0.6%.

ATAI support price is $3.54 and resistance is $3.86 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ATAI shares will trade within this expected range on the day.